Am J Clin Pathol

1. SHEN Z, Wang Y, Xie R, Zhang Q, et al
   Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma.
   Am J Clin Pathol. 2024 Feb 22:aqae012. doi: 10.1093.
   

   >> Share

   
   

   
   Am J Surg Pathol

2. LIBERT D, Zhao S, Younes S, Mosquera AP, et al
   TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
   Am J Surg Pathol. 2024;48:337-352.
   

   >> Share

   
   

   
   Blood

3. ANG Z, Thomas-Tikhonenko A
   Lymphoma immunotherapy: the garden of forking paths.
   Blood. 2024;143:655-657.
   

   >> Share

   
   
4. SCHOOLCRAFT DK, Karrs JX
   Flower cell morphology in high-grade B-cell lymphoma of the maxillary sinus.
   Blood. 2024;143:738.
   

   >> Share

   
   

   
   Br J Dermatol

5. STAMMLER R, Ta VA, Cohen E, Ram-Wolff C, et al
   Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma.
   Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093.
   

   >> Share

   
   
6. JUNG JM, Cho HS, Kim GH, Won CH, et al
   Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study.
   Br J Dermatol. 2024;190:432-434.
   

   >> Share

   
   

   
   Eur J Haematol

7. HEGER JM, d'Hargues Y, Kleinert F, Mattlener J, et al
   Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
   Eur J Haematol. 2024 Feb 18. doi: 10.1111/ejh.14191.
   

   >> Share

   
   
8. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
   Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
   Eur J Haematol. 2024;112:371-378.
   

   >> Share

   
   

   
   Haematologica

9. STATHIS A, Pirosa MC, Orsucci L, Feugier P, et al
   IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
   Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918.
   

   >> Share

   
   
10. MARTIRE G, Lovisa F, Carraro E, Rizzato D, et al
    TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284868.
    

    >> Share

    
    
11. DURAND R, Bellanger C, Kervoelen C, Tessoulin B, et al
    Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284345.
    

    >> Share

    
    

    
    J Biol Chem

12. LIU C, Zhao X, Wang Z, Zhang C, et al
    LncRNA CHROMR/miR-27b-3p/MET axis promotes the proliferation, invasion and contributes to rituximab resistance in diffuse large B-cell lymphoma.
    J Biol Chem. 2024 Feb 15:105762. doi: 10.1016/j.jbc.2024.105762.
    

    >> Share

    
    

    
    Leuk Lymphoma

13. WEI C, Zhai F, Jia C, Zhang W, et al
    Immunochemotherapy triggered reversible cerebral vasoconstriction syndrome in a patient with intravascular large B-cell lymphoma.
    Leuk Lymphoma. 2024 Feb 22:1-4. doi: 10.1080/10428194.2024.2316252.
    

    >> Share

    
    
14. TASHAKORI M, Medeiros LJ
    Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms.
    Leuk Lymphoma. 2024 Feb 21:1-5. doi: 10.1080/10428194.2024.2319691.
    

    >> Share

    
    
15. NEMEC R, Scherrer-Crosbie M, Abramson JS, Redd R, et al
    Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
    Leuk Lymphoma. 2024 Feb 21:1-6. doi: 10.1080/10428194.2024.2317343.
    

    >> Share

    
    
16. BAGGIO D, Wellard C, Chung E, Talaulikar D, et al
    Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
    Leuk Lymphoma. 2023;64:621-627.
    

    >> Share

    
    
17. MURPHY L, Siegele B, Carstens B, Hartman L, et al
    A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
    Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
    

    >> Share

    
    

    
    Leukemia

18. CHEN Z, Huang H, Huang H, Yu L, et al
    Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
    Leukemia. 2024 Feb 20. doi: 10.1038/s41375-024-02171.
    

    >> Share

    
    
19. HOLMQVIST AS, Meng Q, Dai C, Hageman L, et al
    Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report.
    Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02144.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share